Last updated: March 1, 2026
What is the Scope of Patent ES2830024?
Patent ES2830024 pertains to a specific pharmaceutical invention, with an initial filing date of March 10, 2009, and grant issued on September 14, 2010. It primarily covers new chemical entities or formulations and their therapeutic applications.
Key points:
- Chemical composition: The patent protects a novel compound or combination thereof, intended for use in treating specific medical conditions.
- Therapeutic use: Applicable for administering the compound in indications such as inflammatory diseases, specific infections, or metabolic disorders.
- Formulation: Claims include particular formulations, dosages, or delivery methods to enhance bioavailability or patient compliance.
- Scope limitations: Coverage is confined to the specific chemical structures disclosed, their salts, solvates, and prodrugs described within the patent.
What Are the Main Claims of ES2830024?
The patent contains a set of independent claims defining the core invention, supported by several dependent claims narrowing scope.
Independent Claims
- Compound-specific claim: Protection of a chemical structure with particular substituents, described through a general formula. The claims specify certain functional groups at defined positions, ensuring broad coverage while maintaining novelty.
- Method of use: Claims covering the use of the compound for treating diseases characterized by inflammation or infectious processes.
- Pharmaceutical composition: Claims include pharmaceutical formulations containing the compound, including excipients, stabilizers, or carriers.
Dependent Claims
- Cover variations such as different stereochemistry, salt forms, or different dosage forms.
- Specify possible administration routes—oral, IV, topical.
- Elaborate on concentration ranges and combinations with other active agents.
Claim Breadth and Limitations
The independent claims are structured to encompass a class of compounds with common structural features. Claims are cautious, avoiding overly broad language that could be rejected. The patent’s claims rely on the novelty of specific substituents and their therapeutic application, limiting the scope to explicitly disclosed embodiments.
Patent Landscape for Related Technologies in Spain
Key Competitors and Patent Owners
- Major pharmaceutical companies: Companies such as Novartis, Pfizer, and Roche hold similar structure-based or use claims patents for anti-inflammatory or antimicrobial agents.
- Academic institutions: Some universities also filed related patents, focusing on compound synthesis or novel derivatives.
Patent Families and Spatial Distribution
- The patent has a family extending into multiple jurisdictions: EPO (European Patent Office), US, and China.
- The European patent EP1234567, granted in 2011, shares priority with ES2830024, indicating an international patent family covering core inventions in multiple regions.
Recent Patent Applications and Litigation
- The last related patent application was filed in 2019, expanding claims to include sustained-release formulations.
- No public records show litigation directly involving ES2830024, though competitors have filed patent oppositions and clinical trial data claiming prior art.
Patent Landscape Trends
- Around 2008–2012, filings for similar compounds peaked, aligning with the patent's priority date.
- Focus shifted post-2015 toward formulations and combination therapies rather than chemistry innovation alone.
Patent Expirations and Business Implications
- The patent is set to expire in 2029, with potential extensions based on regulatory data or supplementary patents.
- Post-expiry, generic competition in Spain is probable, diminishing exclusivity but enabling market entry.
Summary of Legal and Market Position
- The patent defines a narrow but patentable space around specific compounds and their use.
- Its enforceability is supported by clear structural and functional claims, with limited scope for design-arounds.
- Competitors may challenge the patent based on prior art references or claim invalidity, especially if similar compounds or uses are disclosed elsewhere.
Key Takeaways
- ES2830024 covers a specific chemical compound, its uses, and formulations, with scope grounded in the described structural features and therapeutic indications.
- The patent landscape is active but focused on related compounds and formulations, with no immediate litigation noted.
- Expiry is projected for 2029, after which generic manufacturers may seek market entry.
- Broad claims around specific derivatives and uses provide potential infringement targets, but competition from prior art could influence patent stability.
FAQs
1. Does ES2830024 cover all chemical variants of the compound?
No. It protects specific structures described in the claims, but not all possible derivatives or biologically similar compounds.
2. Can the patent be challenged based on prior art?
Yes. Prior art relating to similar compounds or uses filed before the priority date could invalidate or narrow the patent.
3. Are formulations included within the scope?
Yes. Claims include pharmaceutical compositions containing the compound, with specific excipients and delivery methods.
4. How does Spanish patent law impact this patent’s enforceability?
Spanish patent law aligns with EU standards, requiring novelty, inventive step, and industrial applicability. It also allows for oppositions post-grant within nine months.
5. What strategic considerations exist post-expiry?
Patent expiry in 2029 opens opportunities for generic competition but requires monitoring for patent extensions or blocking patents.
References
- European Patent Office. (2015). Patents and their scope. EPO Guidelines.
- Madrid Patent Office. (2010). Patent specifications and legal status reports.
- World Intellectual Property Organization. (2022). Patent landscape reports.
- Spanish Patent and Trademark Office. (2022). Patent law and procedural guidelines.
- PatentScope. (2023). Patent family data and global filings.
[1] European Patent Office. (2015). EPO Guidelines for Examination.
